1-(3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl)ethanone
• 化学式: C₁₁H₁₉NO
• mdl: MFCD20355338
• 分子量: 181.27
• InChiKey: MJOPUWDJFGMGIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Carbocyclic fused cyclic amines
  申请人：Boehringer Markus

  公开号：US20070112012A1

  公开（公告）日：2007-05-17

  The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X 1 to X 3 , Y 1 to Y 3 , Z, R 1 , R 2 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  该发明涉及化学式(I)中的新型碳环融合的环胺，其中A、X1至X3、Y1至Y3、Z、R1、R2、m和n的定义如描述和权利要求中所定义，以及其生理学上可接受的盐。这些化合物抑制凝血因子Xa，可以用作药物。
• Cannabinoid receptor modulators
  申请人：Chackalamannil Samuel

  公开号：US20070197628A1

  公开（公告）日：2007-08-23

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

  具有通式（I）的一种化合物：或其药用盐、溶剂合物或酯，可用于治疗肥胖、代谢紊乱、成瘾、中枢神经系统疾病、心血管疾病、呼吸系统疾病和消化系统疾病等疾病、紊乱或症状。
• Carbocyclic Fused Cyclic Amines
  申请人：Boehringer Markus

  公开号：US20120122854A1

  公开（公告）日：2012-05-17

  The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X 1 to X 3 , Y 1 to Y 3 , Z, R 1 , R 2 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

  该发明涉及公式（I）中的新型碳环融合环状胺化合物，其中A，X1至X3，Y1至Y3，Z，R1，R2，m和n的定义如说明书和权利要求中所述，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa，并可用作药物。
• Synthetic vaccines against Streptococcus pneumoniae type 1
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US10328141B2

  公开（公告）日：2019-06-25

  The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.

  本发明涉及 1 型肺炎链球菌荚膜多糖中所含糖类结构的全合成，涉及含有通过全合成获得的所述糖类结构的糖结合物，还涉及将这种糖结合物及其药物组合物用于与荚膜多糖中含有所述糖类结构的细菌（更具体地说是与肺炎链球菌有关的细菌）相关疾病的免疫接种。
• HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1894919B1

  公开（公告）日：2012-03-28